Are Peptides coming off of the FDA Category 2 list? A legal breakdown Holt Law You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # Mark your calendar. July 23 24. FDA advisory committee reviewing BPC 157, TB 500, MOTS C, semax, epitalon, KPV, and DSIP for the 503A compounding list. The peptide landscape could shift significantly.